Is Evelo Biosciences, Inc. (EVLO) a Buy, Sell, or Hold?
OTC : EVLO
Evelo Biosciences, Inc.
$0.0001 USD
$0 (0.0%)
- Volume
- 133
- Average Volume
- 577.82
- Market Capitalization
- $1.9K
- P/E Ratio
- 0.00
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.00
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.16
Company Overview
OTC
Craig R. Jalbert
Biotechnology
Healthcare
EVLO
66
US
USD
Liquidity Metrics
-10.24
4.16
4.16
3.87
0.00
Sales & Valuation
-$
0.00
0.00
0.00
-23.37
Profitability
-$26.28
-$114.53M
0.00%
0.00%
-6232.76%
-177.72%
P/E Metrics
0.00
0.00
0.00
Analyst Price Target & Rating
0/5
8 Analysts
%
Financial Health Scores
-53.28
3/9
-$20.82M
$20.63M
$47.33M
-$75.96M
Key Metrics (TTM)
$3.2M
0.00
-0.03
4.16
-6232.76%
-191.76%
-26277098.61%
-5366543.73%
0 days
Company Executives
| Name | Title |
|---|---|
| Douglas Maslin | Senior Director & Immunology Clinical Lead |
| Leslie Wardwell-Scott | Vice President and Head of Corporate Development & Strategic Integration |
| Andrea Itano | Head of Research |
| Chun Zhang | Chief Technical Operations & Quality Officer |
| Duncan McHale MBBS | Chief Medical Officer |
| Craig R. Jalbert CIRA | President, Secretary, Principal Executive, Financial and Accounting Officer & Director |
Poll Results
No votes yet today — be the first to share your view!
About Evelo Biosciences, Inc. (OTC:EVLO) Stock
Evelo Biosciences, Inc. is a biotechnology firm dedicated to identifying and advancing oral biologic therapies for various inflammatory conditions and oncological diseases. Its pipeline includes EDP1815, a whole-microbe compound designed to address inflammatory ailments, currently undergoing Phase 2 clinical trials for conditions such as psoriasis and atopic dermatitis, and also being evaluated for the hyperinflammatory reaction associated with COVID-19. Additional developments include EDP1867, an inactivated oral biologic in Phase 1b for inflammatory diseases; EDP2939, an investigational oral biologic based on extracellular vesicles targeting inflammatory diseases; and EDP1908, a drug candidate focused on cancer. Established in 2014, Evelo Biosciences, Inc. operates from its headquarters ... in Cambridge, Massachusetts.
Frequently Asked Questions
-
What is the current Evelo Biosciences, Inc. (EVLO) stock price?
-
Evelo Biosciences, Inc.(OTC:EVLO) stock price is $0.0001 in the last trading session. During the trading session, EVLO stock reached the peak price of $0.0005 while $0.0001 was the lowest point it dropped to. The percentage change in EVLO stock occurred in the recent session was 0.0% while the dollar amount for the price change in EVLO stock was $0.
-
EVLO's industry and sector of operation?
-
The OTC listed EVLO is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of EVLO?
-
Douglas Maslin | Senior Director & Immunology Clinical Lead
Leslie Wardwell-Scott | Vice President and Head of Corporate Development & Strategic Integration
Andrea Itano | Head of Research
Chun Zhang | Chief Technical Operations & Quality Officer
Duncan McHale MBBS | Chief Medical Officer -
How many employees does EVLO have?
-
Number of EVLO employees currently stands at 66. EVLO operates from 600/700, One Kendall Square, Cambridge, MA 02139, US.
-
Link for EVLO official website?
-
Official Website of EVLO is: https://www.evelobio.com
-
How do I contact EVLO?
-
EVLO could be contacted at phone #617 577 0300 and can also be accessed through its website. EVLO operates from 600/700, One Kendall Square, Cambridge, MA 02139, US.
-
How many shares of EVLO are traded daily?
-
The average number of EVLO shares traded daily for last 3 months was 577.82.
-
What is the market cap of EVLO currently?
-
The market value of EVLO currently stands at $1.9K with its latest stock price at $0.0001